Principais artigos

Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.Texto completo  Resumo

Artigos de referência

1. Ness RB, Hillier SL, Richter HE, et al. Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol. 2002 Oct;100(4):765-72.Texto completo  Resumo

2. Egan ME, Lipsky MS. Diagnosis of vaginitis. Am Fam Physician. 2000 Sep 1;62(5):1095-104. Resumo

3. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1168-76. Resumo

4. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.Texto completo  Resumo

5. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections - 2008. Geneva: World Health Organization; 2012.Texto completo

6. Denning DW, Kneale M, Sobel JD, et al. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018 Nov;18(11):e339-47. Resumo

7. Foxman B, Barlow R, D'Arcy H, et al. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis. 2000 Apr;27(4):230-5. Resumo

8. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997 Oct;314(4):228-31. Resumo

9. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000 May 15;61(10):3090-6. Resumo

10. Hobbs MM, Lapple DM, Lawing LF, et al. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol. 2006 Nov;44(11):3994-9.Texto completo  Resumo

11. Sena AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007 Jan 1;44(1):13-22. Resumo

12. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998 Sep 10;12(13):1699-706. Resumo

13. Wilton L, Kollarova M, Heeley E, et al. Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England. Drug Saf. 2003;26(8):589-97. Resumo

14. Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: risk factors and severity. Obstet Gynecol. 2003 Mar;101(3):548-56.Texto completo  Resumo

15. De Leon EM, Jacober SJ, Sobel JD, et al. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002;2:1. Resumo

16. Joesoef MR, Karundeng A, Runtupalit C, et al. High rate of bacterial vaginosis among women with intrauterine devices in Manado, Indonesia. Contraception. 2001 Sep;64(3):169-72. Resumo

17. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect. 2004 Feb;80(1):58-62.Texto completo  Resumo

18. Otero L, Palacio V, Carreno F, et al. Vulvovaginal candidiasis in female sex workers. Int J STD AIDS. 1998 Sep;9(9):526-30. Resumo

19. Tolosa JE, Chaithongwongwatthana S, Daly S, et al. The International Infections in Pregnancy (IIP) study: variations in the prevalence of bacterial vaginosis and distribution of morphotypes in vaginal smears among pregnant women. Am J Obstet Gynecol. 2006 Nov;195(5):1198-204. Resumo

20. Van Kessel K, Assefi N, Marrazzo J, et al. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review. Obstet Gynecol Surv. 2003 May;58(5):351-8. Resumo

21. Bilardi J, Walker S, McNair R, et al. Women's management of recurrent bacterial vaginosis and experiences of clinical care: a qualitative study. PLoS One. 2016 Mar 24;11(3):e0151794.Texto completo  Resumo

22. Centers for Disease Control and Prevention. Vaginal candidiasis. Oct 2021 [internet publication].Texto completo

23. ACOG Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: vaginitis. Obstet Gynecol. 2006 May (reaffirmed 2017);107(5):1195-206. Resumo

24. British Association for Sexual Health and HIV. UK national guideline for the management of bacterial vaginosis. 2012 [internet publication].Texto completo

25. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010 Dec;13(6):509-22.Texto completo  Resumo

26. Hainer BL, Gibson MV. Vaginitis: diagnosis and treatment. Am Fam Physician. 2011 Apr 1;83(7):807-15.Texto completo  Resumo

27. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983 Jan;74(1):14-22. Resumo

28. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991 Feb;29(2):297-301.Texto completo  Resumo

29. Madico G, Quinn TC, Rompalo A, et al. Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples. J Clin Microbiol. 1998 Nov;36(11):3205-10.Texto completo  Resumo

30. Sharma P, Malla N, Gupta I, et al. A comparison of wet mount, culture and enzyme linked immunosorbent assay for the diagnosis of trichomoniasis in women. Trop Geogr Med. 1991 Jul;43(3):257-60. Resumo

31. van Schalkwyk J, Yudin MH; Infectious Diseases Committee, Society of Obstetricians and Gynaecologists of Canada. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. J Obstet Gynaecol Can. 2015 Mar;37(3):266-74.Texto completo  Resumo

32. US Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008 Feb 5;148(3):214-9.Texto completo  Resumo

33. Yudin MH, Money DM. No. 211-Screening and management of bacterial vaginosis in pregnancy. J Obstet Gynaecol Can. 2017 Aug;39(8):e184-e191.Texto completo  Resumo

34. Fethers K, Marks C, Mindel A, et al. Sexually transmitted infections and risk behaviours in women who have sex with women. Sex Transm Infect. 2000 Oct;76(5):345-9.Texto completo  Resumo

35. Evans AL, Scally AJ, Wellard SJ, et al. Prevalence of bacterial vaginosis in lesbians and heterosexual women in a community setting. Sex Transm Infect. 2007 Oct;83(6):470-5.Texto completo  Resumo

36. Brandt M, Abels C, May T, et al. Intravaginally applied metronidazole is as effective as orally applied in the treatment of bacterial vaginosis, but exhibits significantly less side effects. Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):158-62. Resumo

37. Oduyebo OO, Anorlu RI, Ogunsola FT, et al. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006055.Texto completo  Resumo

38. Menard JP. Antibacterial treatment of bacterial vaginosis: current and emerging therapies. Int J Womens Health. 2011;3:295-305.Texto completo  Resumo

39. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006 May;194(5):1283-9. Resumo

40. Boselli F, Petrella E, Campedelli A, et al. Efficacy and tolerability of fitostimoline (vaginal cream, ovules, and vaginal washing) and of benzydamine hydrochloride (tantum rosa vaginal cream and vaginal washing) in the topical treatment of symptoms of bacterial vaginosis. ISRN Obstet Gynecol. 2012;2012:183403.Texto completo  Resumo

41. Verstraelen H, Verhelst R, Roelens K, et al. Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review. BMC Infect Dis. 2012 Jun 28;12:148.Texto completo  Resumo

42. Weissenbacher ER, Donders G, Unzeitig V, et al. A comparison of dequalinium chloride vaginal tablets (Fluomizin®) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest. 2012;73(1):8-15.Texto completo  Resumo

43. Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med. 2011 Mar;8(3):666-74. Resumo

44. Chollet JA. Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Prefer Adherence. 2011;5:571-4.Texto completo  Resumo

45. Gülmezoglu AM, Azhar M. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev. 2011 May 11;(5):CD000220.Texto completo  Resumo

46. Castelo-Branco C, Cancelo MJ. Compounds for the treatment of atropic vaginitis. Expert Opin Ther Pat. 2008 Nov 18;18(12):1385-94.

47. Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):85-92. Resumo

48. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016 Aug 31;(8):CD001500.Texto completo  Resumo

49. Wolner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA. 1989 Jan 27;261(4):571-6. Resumo

50. Petersen EE, Genet M, Caserini M, et al. Efficacy of vitamin C vaginal tablets in the treatment of bacterial vaginosis: a randomised, double blind, placebo controlled clinical trial. Arzneimittelforschung. 2011;61(4):260-5. Resumo

51. Schwebke JR, Morgan FG Jr, Koltun W, et al. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017 Dec;217(6):678;e1-678;e9. Resumo

52. Portman DJ, Bachmann GA, Simon JA, et al. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013 Jun;20(6):623-30. Resumo

53. Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303). Clin Infect Dis. 2021 Sep 1:ciab750.Texto completo  Resumo

54. Sobel R, Nyirjesy P, Ghannoum MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). BJOG. 2022 Feb;129(3):412-20.Texto completo  Resumo

55. Svare JA, Schmidt H, Hansen BB, et al. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG. 2006 Dec;113(12):1419-25. Resumo

56. McGregor JA, French JI, Parker R, et al. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation. Am J Obstet Gynecol. 1995 Jul;173(1):157-67. Resumo

57. Brocklehurst P, Gordon A, Heatley E, et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000262.Texto completo  Resumo

58. St John E, Mares D, Spear GT. Bacterial vaginosis and host immunity. Curr HIV/AIDS Rep. 2007 Feb;4(1):22-8. Resumo

59. McClelland RS, Sangaré L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis. 2007 Mar 1;195(5):698-702.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal